The Supreme Court granted certiorari to review whether a generic drugmaker that fully carves out a patented use from its ...
On January 4, 2022, the District Court for the District of Delaware granted Hikma Pharmaceuticals USA Inc.’s (“Hikma”) motion to dismiss Amarin Pharma Inc.’s (“Amarin”) infringement claims, finding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results